Table 2 |.
Fine-Gray model for AKI within 6 months of initiation of triplet therapy or pembrolizumab monotherapy in the MGB cohort
| Univariate analysis | Multivariable model | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | P value | aHR | 95% CI | P value |
| Triplet therapy (vs. monotherapy) | 1.25 | 0.93–1.68 | 0.14 | 1.19 | 0.88–1.61 | 0.25 |
| Female | 2.17 | 1.59–2.96 | <0.01 | 2.41 | 1.76–3.30 | <0.01 |
| Age | 0.99 | 0.98–1.00 | 0.04 | 1.00 | 0.98–1.02 | 0.83 |
| Baseline eGFR (per 1 ml/min per 1.73 m2) | 1.02 | 1.01 −1.02 | <0.01 | 1.02 | 1.01–1.04 | <0.01 |
| BMI | ||||||
| 20–25 vs. <20 | 0.95 | 0.46–1.97 | 0.84 | — | — | — |
| 25–30 vs. <20 | 0.79 | 0.38–1.66 | 0.64 | — | — | — |
| ≥30 vs. <20 | 0.83 | 0.38–1.79 | 0.76 | — | — | — |
| Hypertension | 1.15 | 0.85–1.55 | 0.37 | — | — | — |
| Diabetes | 0.96 | 0.66–1.38 | 0.81 | — | — | — |
| Coronary artery disease | 1.49 | 1.10–2.02 | 0.01 | 1.44 | 1.03–2.02 | 0.03 |
| Cirrhosis | 0.74 | 0.12–4.52 | 0.75 | — | — | — |
| ACEI/ARBs | 1.39 | 1.04–1.87 | 0.03 | 1.63 | 1.19–2.22 | <0.01 |
| Diuretics | 1.13 | 0.83–1.53 | 0.44 | — | — | — |
| PPIs | 1.03 | 0.77–1.38 | 0.85 | — | — | — |
| Charlson comorbidity score | 1.04 | 0.99–1.09 | 0.15 | 1.05 | 0.99–1.11 | 0.13 |
aHR, adjusted hazard ratio; ACEI/ARB, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker; AKI, acute kidney injury; BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; ICPi-AKI, immune checkpoint inhibitor-associated acute kidney injury; MGB, Massachusetts General Brigham; PPI, proton pump inhibitor.
The Fine-Gray model takes into account the competing risk for death. The multivariable model evaluates the risk of AKI in patients treated with triplet versus monotherapy, adjusting for age, sex, baseline eGFR, coronary artery disease, Charlson comorbidity score, and ACEI/ARB use.